Remote loading of sparingly water-soluble drugs into liposomes

• US 10,507,182 B2
• Filed: 09/10/2018
• Issued: 12/17/2019
• Est. Priority Date: 02/01/2013
• Status: Active Grant

• Current Assignee: Celator Pharmaceuticals Inc.
• Original Assignee: Zoneone Pharma, Inc.
• Inventors: Hayes, Mark E., Noble, Charles O., Szoka, Jr., Francis C.
• Primary Examiner(s): Kishore, Gollamudi S
• Application Number:
  US16/126,799
• Publication Number:
  US 20190110991A1
• Time in Patent Office: 463 Days
• CPC Class Codes: A61K 31/4196 1,2,4-Triazoles
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: A61K 9/1275 Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
• CPC Class Codes: A61K 9/1278 Post-loading, e.g. by ion or pH gradient
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: B01J 13/08 Simple coacervation, i.e. addition of highly hydrophilic material combined with spraying B01J13/043; combined with mechanical division B01J13/04

Abstract

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading capability is retained. The process is scalable and, in liposomes in which the lipid composition and remote loading agent are optimized, the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and prolonged drug retention when the liposome encapsulated drug is administered to a subject.

Claims

1. A pharmaceutical formulation comprising carfilzomib encapsulated within a liposome, said liposome comprising a lipid membrane defining an internal aqueous compartment comprising said encapsulated carfilzomib, said lipid membrane comprising:

(a) sphingomyelin (SM);

(b) cholesterol; and

(c) PEG-(1,2-distearoyl-sn-glycero-3-phosphoethanolamine) (PEG-DSPE), wherein said formulation is selected from a lyophilized formulation and a formulation in which said liposome is suspended in a pharmaceutically acceptable diluent.

2. The pharmaceutical formulation according to claim 1, manufactured by a method comprising:

(a) preparing a suspension of said liposome in an aqueous solution of an ammonium salt of a carbohydrate sulfate forming a first population of said ammonium salt encapsulated within said liposome and a second population of said salt external to said liposome;

(b) replacing said salt external to said liposome with an aqueous buffer, thereby forming a gradient of said carbohydrate sulfate across said lipid membrane; and

(c) adding a solution of carfilzomib in an aprotic solvent to the suspension formed in (b), forming a carfilzomib precipitate allowing carfilzomib to traverse said lipid membrane, concentrating in said internal aqueous compartment, thereby encapsulating said carfilzomib.

3. The pharmaceutical formulation according to claim 1, wherein said liposomes are from about 40 nm to about 150 nm in diameter.

4. The pharmaceutical formulation of claim 1, wherein said cholesterol is present in a molar ratio to the total lipid of from about 25 mole percent to about 50 mole percent.

5. The pharmaceutical formulation according to claim 1, wherein said SM is present in a molar ratio to the total lipids of from about 45 mole percent to about 65 mmole percent.

6. The pharmaceutical formulation of claim 1, wherein said PEG-DSPE is present in a molar ratio to the total lipids of from about 0 mole percent to about 10 mole percent.

7. The pharmaceutical formulation of claim 1, wherein said lipid membrane comprises a molar ratio of components of about 55 mole percent SM, about 45 mole percent cholesterol and about 2.8 mole percent PEG-DSPE.

8. The pharmaceutical formulation according to claim 1, wherein said liposome further encapsulates said carbohydrate sulfate.

9. The pharmaceutical formulation according to claim 2, wherein said ammonium salt of a carbohydrate sulfate is selected from ammonium dextran sulfate, triethylammonium dextran sulfate.

10. The pharmaceutical formulation of claim 1, wherein at least a fraction of said carfilzomib is suspended in said internal aqueous compartment.

11. The pharmaceutical formulation according to claim 2, wherein the aprotic solvent is selected from dimethylsulfoxide, dioxane, tetrahydrofuran, dimethylformamide, acetonitrile, dimethylacetamide, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, polyethylene glycol.

12. The pharmaceutical formulation according to claim 1, wherein the carfilzomib to lipid ratio is from about 30 mg of carfilzomib to about 90 mg of carfilzomib to from about 90 mg of lipid to about 250 mg lipid.

13. The pharmaceutical formulation according to claim 11, wherein the carfilzomib to lipid ratio is about 60 mg carfilzomib to about 170 mg lipid.

14. The pharmaceutical formulation according to claim 11, wherein the liposomes of said formulation have a diameter of from about 40 nm to about 150 nm.

15. The pharmaceutical formulation according to claim 1, wherein said formulation is in a unit dosage format comprising about 50 mg to about 70 mg of carfilzomib.

16. The pharmaceutical formulation according to claim 1, wherein said carfilzomib has an in vivo T_1/2 of from about 2 hours to about 12 hours in subject to whom it has been administered.

18. The pharmaceutical formulation of claim 15, wherein said population of liposomes further encapsulate dextran sulfate.

19. The pharmaceutical formulation of claim 16, wherein said formulation is selected from a lyophilized formulation and a formulation in which said liposomes are suspended in a pharmaceutically acceptable diluent.

17. A pharmaceutical formulation comprising from about 50 mg to about 70 mg of carfilzomib encapsulated within an internal aqueous compartment of a population of liposomes, said liposomes comprising a lipid membrane, defining said internal aqueous compartment comprising said encapsulated carfilzomib, said lipid membrane comprising, (a) from about 45 mole percent to about 65 mol percent sphingomyelin (SM);

(b) from about 25 mole percent to about 50 mole percent cholesterol; and

(c) from about 0 mmole percent to about 10 mole percent PEG-(1,2-distearoyl-sn-glycero-3-phosphoethanolamine) (PEG-DSPE).

20. A pharmaceutical formulation comprising about 60 mg of carfilzomib encapsulated within a of population of liposomes whose mass is from about 90 mg to about 250 mg, said liposomes comprising a lipid membrane defining an internal aqueous compartment comprising said encapsulated carfilzomib, said lipid membrane comprising a molar ratio of components:

(a) of about 55 mole percent sphingomyelin (SM);

(b) about 45 mole percent cholesterol; and

(c) about 2.8 mmole percent PEG-(1,2-distearoyl-sn-glycero-3-phosphoethanolamine) (PEG-DSPE);

said formulation selected from a lyophilized formulation and a formulation in which said liposomes are suspended in a pharmaceutically acceptable diluent.